Clinical Trial Update: Observational Study of Blinatumomab

View source ↗

Summary

An observational study evaluating Blinatumomab (Blincyto) in routine clinical practice has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• BLINCYTO (BLINATUMOMAB)

Snippet

Sponsor: Amgen | Conditions: Blincyto Use in Routine Clinical Practice | Status: COMPLETED